UroGen Pharma Ltd.'s SEC filings document operating results, product revenue disclosures, financing agreements and governance matters for a biotechnology company focused on urothelial and specialty cancers. Recent 8-K reports furnish quarterly and annual financial results tied to JELMYTO and ZUSDURI, commercial launch updates, research and development expenses, reimbursement matters and pipeline disclosures involving UGN-103 and UGN-501.
Other filings describe material definitive agreements, including term-loan refinancing and credit arrangements with BioPharma Credit entities, as well as capital-structure information for ordinary shares listed on Nasdaq. Definitive proxy statements cover board matters, executive compensation, equity awards, pay-versus-performance tables and shareholder voting matters.
The Toronto-Dominion Bank and TD Securities Inc. report beneficial ownership of 3,371,263 ordinary shares of UroGen Pharma Ltd., representing 6.9% of the outstanding class of ordinary shares, par value NIS 0.01 per share.
The Toronto-Dominion Bank has sole voting and dispositive power over 3,269,957 shares, while TD Securities Inc. has sole voting and dispositive power over 101,306 shares. TD Securities Inc. is wholly owned by The Toronto-Dominion Bank. The Toronto-Dominion Bank may be deemed to hold an indirect interest in TD Securities Inc.’s shares through this ownership but expressly disclaims beneficial ownership of those shares except to the extent of its pecuniary interest. The reporting persons also state that nothing in the disclosure should be construed as them acting as part of a group with any other person regarding UroGen Pharma securities.
UroGen Pharma reported sharply higher oncology product sales for the quarter ended June 30, 2026. Net revenue reached $72.5 million, up from $24.2 million a year earlier, driven by Zusduri ($50.4 million) alongside Jelmyto ($22.0 million). Gross profit increased to $65.9 million, and operating results swung to a small income of $0.1 million from a $41.4 million loss. After interest, financing costs and income taxes, net loss narrowed to $14.4 million (loss per share $0.28) versus $49.9 million (loss per share $1.05). For the first half of 2026, revenue was $123.4 million with a net loss of $37.9 million.
At June 30, 2026, UroGen held cash, cash equivalents and marketable securities totaling $108.0 million, plus accounts receivable of $88.8 million, against total liabilities of $385.0 million. Key obligations include a prepaid forward liability of $125.1 million tied to Jelmyto and Zusduri sales and long-term debt of $188.7 million under a Pharmakon term loan maturing in 2030–2031. Shareholders’ deficit was $132.4 million on an accumulated deficit of $997.6 million.
Net cash used in operating activities was $78.3 million for the first six months of 2026. Management states that existing cash and marketable securities are expected to fund operations for more than one year, with future performance heavily dependent on commercialization of Jelmyto and Zusduri.
UroGen Pharma reported strong second-quarter 2026 results, highlighted by the commercial launch of ZUSDURI. Total revenue was $72.5 million, up from $24.2 million a year earlier, including $50.4 million of ZUSDURI revenue. JELMYTO continued to contribute as a marketed product.
Operating performance improved markedly: gross profit reached $65.9 million and operating income turned slightly positive at $0.1 million, while net loss narrowed to $14.4 million, or $0.28 per share, from $49.9 million. Cash, cash equivalents and marketable securities totaled $108.0 million as of June 30, 2026.
The company reiterated 2026 JELMYTO net product revenue guidance of $97–$101 million and raised full-year 2026 operating expense guidance to $260–$270 million, including $20–$24 million of non-cash share-based compensation, reflecting accelerated investment behind ZUSDURI and pipeline candidates UGN-103 and UGN-501. A new U.S. patent allowance is expected to extend IP coverage for ZUSDURI and UGN-103 into July 2044.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg reported an open-market sale of 10,000 Ordinary Shares of URGN at a weighted average price of $40.00 per share. The transaction was made pursuant to a duly adopted Rule 10b5-1(c) trading plan and represents the final sale under that plan. Following this sale, Schoenberg holds 119,763 Ordinary Shares directly.
UroGen Pharma Ltd. reported proposed sales of common stock by an affiliate via Form 144. The filing lists two dispositions of 10,000 shares each sold on 05/08/2026 and 06/22/2026 for $300,048 and $350,143, respectively, and references a stock option exercise dated 01/27/2023.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg sold 10,000 Ordinary Shares in an open-market transaction at a weighted average price of $35.01 per share, with trades ranging from $35.00 to $35.08, under a pre-adopted Rule 10b5-1(c) trading plan. Following this sale on June 22, 2026, he directly holds 129,763 Ordinary Shares.
UroGen Pharma director Daniel George Wildman received new equity awards. He was granted 8,000 restricted stock units and stock options for 10,000 ordinary shares at an exercise price of $34.99 per share. Both the RSUs and options vest in equal quarterly installments over one year, contingent on his continuous service.
UroGen Pharma Ltd. director James A. Robinson Jr. reported equity awards that increase his potential ownership in the company. On June 22, 2026, he received 8,000 restricted stock units (RSUs), each representing one ordinary share upon vesting. He was also granted stock options on 10,000 ordinary shares with an exercise price of $34.99 per share and an expiration date of June 22, 2036. Both the RSUs and the option shares vest in equal quarterly installments over one year, contingent on his continued board service. After these grants, his reported holdings from these awards are 8,000 RSUs and 10,000 options, reflecting routine director compensation rather than open‑market trading.
UroGen Pharma Ltd. director Stuart Holden received a grant of stock options covering 20,000 ordinary shares. The options have an exercise price of $34.99 per share, expire on June 22, 2036, and vest in equal quarterly installments over one year, subject to his continuous service. Following this grant, he holds 20,000 options directly.
UroGen Pharma Ltd. director Cynthia M. Butitta received new equity awards as part of her compensation. She was granted 8,000 restricted stock units, each representing a right to receive one ordinary share. These RSUs will vest in equal quarterly installments over one year, so the award is earned gradually as service continues.
She was also granted stock options covering 10,000 ordinary shares at an exercise price of $34.99 per share, expiring on June 22, 2036. The option shares vest in equal quarterly installments over one year, aligning her incentives with long‑term shareholder value rather than reflecting any open‑market buying or selling.